RCS - Creo Medical Group - UK & EU Commercial launch of SpydrBlade™ Flex

Creo MedicalAnnouncement

20/03/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250320:nRST4050Ba&default-theme=true

RNS Number : 4050B  Creo Medical Group PLC  20 March 2025

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

UK & EU Commercial launch of SpydrBlade™ Flex

 

A world Leading NHS Endoscopy unit first commercial customer of SpydrBlade
Flex for Lower GI colorectal resections

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the
emerging field of minimally invasive surgical endoscopy for pre-cancer and
cancer patients, announces the commercial launch and first customer of its
SpydrBlade Flex
(https://www.creomedical.com/en/kamaptive-technology/spydrblade-flex) (1)
technology, a unique multi-modal endoscopic device designed for precision and
adaptability in endoscopic procedures, in the UK and Europe.

 

Following extensive pre-launch global clinical activity, this first customer
marks the UK & EU commercial launch of SpydrBlade Flex, and is being
pioneered in St Mark's Hospital in NW London, one of the UK's leading
Endoscopy Units and recognised as a world centre of excellence by the WEO
(World Endoscopy Organisation). St Mark's Hospital is also an established and
regular user of Creo's Speedboat UltraSlim.

 

Creo will be ramping up the full commercial launch via its core sales channels
in the UK and the EU as well as other international territories, including the
US, once local regulatory approvals have been received.

 

SpydrBlade Flex will be showcased amongst the latest endoscopy technology at
the upcoming ESGE (European Society of Gastrointestinal Endoscopy) Days 2025
conference in Barcelona in April.

 

Craig Gulliford, Chief Executive Officer of Creo, said: "We are delighted to
announce the commercial launch of our SpydrBlade Flex product in the UK and
across Europe and it is fitting that the first commercial customer is such a
recognised centre as St Marks. SpydrBlade really is one of the most advanced
surgical tools and again, Creo have pioneered the introduction of this
technology into the tiny footprint of a flexible endoscopic instrument.
Speedboat UltraSlim alongside SpydrBlade Flex will enhance the care of
patients with a wide range of conditions ranging from cancers to swallowing
disorders, as well as their increasing use in the rapidly growing treatment of
Barriatric conditions.

 

"Both products will continue to help move the point of care from Surgery and
the operating theatre to the endoscopy room allowing us to further reduce
surgical waiting lists not only in the NHS, but globally. We expect to see
further commercial traction as more people adopt our new technology, and
following further regulatory approvals, including the FDA clearance to allow
our commercial launch in the US."

 

 

Above: The SpydrBlade Flex "the most versatile dissection tool in flexible
endoscopy"

Notes

(1)https://www.creomedical.com/en/kamaptive-technology/spydrblade-flex
(https://www.creomedical.com/en/kamaptive-technology/spydrblade-flex)

 

 

For further information please contact:

 

 Creo Medical Group plc                                                        www.creomedical.com
                                                                               (https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)
 Richard Craven, Company Secretary                                             Via Walbrook PR

 Deutsche Numis (Nominated Adviser, Sole Broker and Financial Adviser)         +44 (0)20 7260 1000

 Freddie Barnfield / Duncan Monteith / Euan Brown / Sher Shah

 Walbrook PR Ltd                      Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com (mailto:creo@walbrookpr.com)
 Paul McManus / Alice Woodings        Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 Phillip Marriage                     Mob: +44 (0)7867 984 082

 

 

About Creo Medical

Creo is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation,
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRASFLEDUEISEDD